SRXH
SRx Health Solutions Inc.
Drug Manufacturers - General
Market Cap$1M
5Y Perf.-94.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SRXH vs ALHC
Revenue, margins, valuation, and 5-year total return — side by side.
ALHC
Alignment Healthcare, Inc.
Medical - Healthcare Plans
Market Cap$3.73B
5Y Perf.+3.0%
SRXH vs ALHC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SRXH | ALHC |
|---|---|---|
| Industry | Drug Manufacturers - General | Medical - Healthcare Plans |
| Market Cap | $1M | $3.73B |
| Revenue (TTM) | $119M | $4.26B |
| Net Income (TTM) | $-11M | $20M |
| Gross Margin | 19.9% | 9.0% |
| Operating Margin | -4.9% | 0.8% |
| Forward P/E | — | 140.9x |
| Total Debt | $39M | $338M |
| Cash & Equiv. | $2M | $578M |
SRXH vs ALHC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SRXH
ALHC
| Stock | Apr 25 | May 26 | Return |
|---|---|---|---|
| SRx Health Solution… (SRXH) | 100 | 5.8 | -94.2% |
| Alignment Healthcar… (ALHC) | 100 | 103.0 | +3.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SRXH vs ALHC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ALHC leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. SRx Health Solutions Inc. is the stronger pick specifically for valuation and capital efficiency. As sector peers, any of these can serve as alternatives in the same allocation.
SRXH
SRx Health Solutions Inc.
The Value Play
SRXH is the clearest fit if your priority is value.
- Better valuation composite
Best for: value
ALHC
Alignment Healthcare, Inc.
The Insurance Pick
ALHC carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 46.1%, EPS growth 99.4%, 3Y rev CAGR 40.2%
- 5.4% 10Y total return vs SRXH's -94.6%
- Lower volatility, beta 0.75, current ratio 1.74x
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ALHC | 46.1% revenue growth vs SRXH's 28.4% |
| Value | SRXH | Better valuation composite |
| Quality / Margins | ALHC | 0.5% margin vs SRXH's -9.4% |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ALHC | +17.6% vs SRXH's -84.6% |
| Efficiency (ROA) | ALHC | 1.8% ROA vs SRXH's -22.4% |
SRXH vs ALHC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2023
SRXH vs ALHC — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLALHCLAGGINGSRXH
SRXHSRx Health Solutions …
1leads
ALHCAlignment Healthcare,…
3leads
6 Total Categories
CATEGORYLEADERvs SRXHMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ALHC3/4
Valuation MetricsMultiples, price ratios, and targets
SRXH2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ALHC5/6
Total Returns1Y, 3Y, 5Y total returns with dividends
ALHC6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ALHC leads this category, winning 3 of 4 comparable metrics.
Income & Cash Flow (Last 12 Months)
ALHC is the larger business by revenue, generating $4.3B annually — 35.8x SRXH's $119M. ALHC is the more profitable business, keeping 0.5% of every revenue dollar as net income compared to SRXH's -9.4%.
| Metric | SRXHSRx Health Soluti… | ALHCAlignment Healthc… |
|---|---|---|
| RevenueTrailing 12 months | $119M | $4.3B |
| EBITDAEarnings before interest/tax | — | $66M |
| Net IncomeAfter-tax profit | — | $20M |
| Free Cash FlowCash after capex | — | $237M |
| Gross MarginGross profit ÷ Revenue | +19.9% | +9.0% |
| Operating MarginEBIT ÷ Revenue | -4.9% | +0.8% |
| Net MarginNet income ÷ Revenue | -9.4% | +0.5% |
| FCF MarginFCF ÷ Revenue | +1.3% | +5.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +33.3% |
| EPS Growth (YoY)Latest quarter vs prior year | — | +2.1% |
ALHC leads this category, winning 3 of 4 comparable metrics.
Valuation Metrics
SRXH leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | SRXHSRx Health Soluti… | ALHCAlignment Healthc… |
|---|---|---|
| Market CapShares × price | $1M | $3.7B |
| Enterprise ValueMkt cap + debt − cash | $29M | $3.5B |
| Trailing P/EPrice ÷ TTM EPS | -0.17x | -4932.43x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 140.93x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 77.12x |
| Price / SalesMarket cap ÷ Revenue | 0.02x | 0.94x |
| Price / BookPrice ÷ Book value/share | — | 20.16x |
| Price / FCFMarket cap ÷ FCF | 1.20x | 32.95x |
SRXH leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
ALHC leads this category, winning 5 of 6 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), ALHC scores 6/9 vs SRXH's 3/9, reflecting solid financial health.
| Metric | SRXHSRx Health Soluti… | ALHCAlignment Healthc… |
|---|---|---|
| ROE (TTM)Return on equity | — | +11.5% |
| ROA (TTM)Return on assets | -22.4% | +1.8% |
| ROICReturn on invested capital | -18.1% | — |
| ROCEReturn on capital employed | -98.8% | +2.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 6 |
| Debt / EquityFinancial leverage | — | 1.89x |
| Net DebtTotal debt minus cash | $37M | -$240M |
| Cash & Equiv.Liquid assets | $2M | $578M |
| Total DebtShort + long-term debt | $39M | $338M |
| Interest CoverageEBIT ÷ Interest expense | -2.83x | 1.27x |
ALHC leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
ALHC leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALHC five years ago would be worth $7,726 today (with dividends reinvested), compared to $536 for SRXH. Over the past 12 months, ALHC leads with a +17.6% total return vs SRXH's -84.6%. The 3-year compound annual growth rate (CAGR) favors ALHC at 36.2% vs SRXH's -62.3% — a key indicator of consistent wealth creation.
| Metric | SRXHSRx Health Soluti… | ALHCAlignment Healthc… |
|---|---|---|
| YTD ReturnYear-to-date | -52.9% | -9.7% |
| 1-Year ReturnPast 12 months | -84.6% | +17.6% |
| 3-Year ReturnCumulative with dividends | -94.6% | +152.4% |
| 5-Year ReturnCumulative with dividends | -94.6% | -22.7% |
| 10-Year ReturnCumulative with dividends | -94.6% | +5.4% |
| CAGR (3Y)Annualised 3-year return | -62.3% | +36.2% |
ALHC leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — SRXH and ALHC each lead in 1 of 2 comparable metrics.
Risk & Volatility
SRXH is the less volatile stock with a -0.32 beta — it tends to amplify market swings less than ALHC's 0.75 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALHC currently trades 76.5% from its 52-week high vs SRXH's 9.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SRXHSRx Health Soluti… | ALHCAlignment Healthc… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.32x | 0.75x |
| 52-Week HighHighest price in past year | $1.25 | $23.87 |
| 52-Week LowLowest price in past year | $0.08 | $11.63 |
| % of 52W HighCurrent price vs 52-week peak | +9.0% | +76.5% |
| RSI (14)Momentum oscillator 0–100 | 41.4 | 37.3 |
| Avg Volume (50D)Average daily shares traded | 22.0M | 3.6M |
Evenly matched — SRXH and ALHC each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | SRXHSRx Health Soluti… | ALHCAlignment Healthc… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $24.83 |
| # AnalystsCovering analysts | — | 16 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ALHC leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). SRXH leads in 1 (Valuation Metrics). 1 tied.
Best OverallAlignment Healthcare, Inc. (ALHC)Leads 3 of 6 categories
Loading custom metrics...
SRXH vs ALHC: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SRXH or ALHC a better buy right now?
For growth investors, Alignment Healthcare, Inc.
(ALHC) is the stronger pick with 46. 1% revenue growth year-over-year, versus 28. 4% for SRx Health Solutions Inc. (SRXH). Analysts rate Alignment Healthcare, Inc. (ALHC) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SRXH or ALHC?
Over the past 5 years, Alignment Healthcare, Inc.
(ALHC) delivered a total return of -22. 7%, compared to -94. 6% for SRx Health Solutions Inc. (SRXH). Over 10 years, the gap is even starker: ALHC returned +5. 4% versus SRXH's -94. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SRXH or ALHC?
By beta (market sensitivity over 5 years), SRx Health Solutions Inc.
(SRXH) is the lower-risk stock at -0. 32β versus Alignment Healthcare, Inc. 's 0. 75β — meaning ALHC is approximately -332% more volatile than SRXH relative to the S&P 500.
04Which is growing faster — SRXH or ALHC?
By revenue growth (latest reported year), Alignment Healthcare, Inc.
(ALHC) is pulling ahead at 46. 1% versus 28. 4% for SRx Health Solutions Inc. (SRXH). On earnings-per-share growth, the picture is similar: Alignment Healthcare, Inc. grew EPS 99. 4% year-over-year, compared to 74. 1% for SRx Health Solutions Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SRXH or ALHC?
Alignment Healthcare, Inc.
(ALHC) is the more profitable company, earning -0. 0% net margin versus -9. 4% for SRx Health Solutions Inc. — meaning it keeps -0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALHC leads at 0. 4% versus -4. 9% for SRXH. At the gross margin level — before operating expenses — SRXH leads at 19. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — SRXH or ALHC?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is SRXH or ALHC better for a retirement portfolio?
For long-horizon retirement investors, SRx Health Solutions Inc.
(SRXH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 32)). Both have compounded well over 10 years (SRXH: -94. 6%, ALHC: +5. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SRXH and ALHC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(SRXH: 28.4% · ALHC: 33.3%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.